Skip to main content

Table 7 Efficacy of recent clinical trials with liposomal daunorubicin in mono or combined therapy

From: Nanomedicine review: clinical developments in liposomal applications

CR (%)M-EFS (months)OS rate (%)M-OS (months)
Inman (2017)2016IIIAMLCPX-351153100 units/m2/day47.72.5341.5a
Cortes et al. (2015)2015IIAMLCPX-35181100 units/m2/day49.4436c8.5
Lancet et al. (2014)2014IIAMLCPX-35185100 units/m2/day66.76.514.7
Gergis et al. (2013)2013IAMLCPX-35136Dose escalationa72.23.2b37c8.3
Kaspers et al. (2013)2013IIIAMLDaunoXome® + fludarabine + cytarabine + filgrastim19760 mg/m2/day + 30 mg/m2/day + 2000 mg/m2/day + 200 μg/m2/dose6940d
Creutzig et al. (2013)2013IIIAMLLiposomal daunorubicin25760 mg/m2/day8959%e76e
  1. CR or complete remission, was defined as < 5% leukemic blasts in bone marrow with signs of normal hematopoiesis and of regeneration of normal peripheral blood cell production (platelets > 50 × 109/L without transfusions, neutrophils > 1.0 × 109/L) and no leukemic cells in the peripheral blood or anywhere else (Kaspers et al. 2013)
  2. LF liposomal formulation, n number of patients, AML acute myeloid leukemia
  3. aIt is not described here
  4. bLeukemia-free survival
  5. cAt 1 year
  6. dAt 4 years
  7. eAt 5 years